Invivyd (IVVD) Revenue (2024 - 2025)
Invivyd posted quarterly Revenue of $17.2 million for Q4 2025, up 24.51% year-on-year from $13.8 million in Q4 2024, and up 31.06% on a QoQ basis from $13.1 million in Q3 2025.
Invivyd (IVVD) has 2 years of Revenue data on file, last reported at $17.2 million in Q4 2025.
- For the quarter ending Q4 2025, Revenue rose 24.51% year-over-year to $17.2 million; the trailing twelve-month figure through Dec 2025 stood at $53.4 million (up 110.47% YoY), and the FY2025 full-year result was $53.4 million, up 110.47% from the prior year.
- Revenue for Q4 2025 stood at $17.2 million, up from $13.1 million in the prior quarter.
- Across five years, Revenue topped out at $17.2 million in Q4 2025 and bottomed at $2.3 million in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Invivyd | 208.38 Mn | -18.31 Mn | - | 17.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 17.21 Mn |
| Sep 30, 2025 | 13.13 Mn |
| Jun 30, 2025 | 11.79 Mn |
| Mar 31, 2025 | 11.30 Mn |
| Dec 31, 2024 | 13.82 Mn |
| Sep 30, 2024 | 9.30 Mn |
| Jun 30, 2024 | 2.26 Mn |